written on 19.05.2014

Kamada slumps on reticence to explain 'positive signal' in AAT trial


Kamada of Israel believes that despite missing the primary endpoint in a Phase II/III trial, positive secondary endpoint data and results from a recently initiated US Phase II trial will be enough to persuade regulators to approve its inhaled alpha-1…